According to the deal, Beactica will leverage Sprint drug discovery platform in identifying allosteric modulators against certain central nervous system proteins for supporting the Janssen’s discovery efforts.
The research services contract between the firms began in 2011. Financial terms of the deal were kept confidential.
Beactica CEO Dr Per Kallblad said, "The extension of our relationship testifies to the ability of our Sprint platform to generate novel, high-quality medicinal chemistry starting points against challenging drug targets."
Specialist drug discovery company Beactica uses its methodologies to analyze the molecular interactions of molecules to produce mechanistically defined therapeutics.